{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:36:35Z","timestamp":1783611395011,"version":"3.55.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1008473"],"award-info":[{"award-number":["APP1008473"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.phrs.2015.03.004","type":"journal-article","created":{"date-parts":[[2015,3,14]],"date-time":"2015-03-14T16:35:22Z","timestamp":1426350922000},"page":"20-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Risperidone-induced weight gain and reduced locomotor activity in juvenile female rats: The role of histaminergic and NPY pathways"],"prefix":"10.1016","volume":"95-96","author":[{"given":"Jiamei","family":"Lian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"De Santis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2015.03.004_bib0395","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.euroneuro.2011.04.001","article-title":"Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies","volume":"21","author":"Zuddas","year":"2011","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2015.03.004_bib0400","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.euroneuro.2010.07.002","article-title":"Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons","volume":"21","author":"Fraguas","year":"2011","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2015.03.004_bib0405","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/schbul\/sbq040","article-title":"Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia","volume":"37","author":"Piontkewitz","year":"2011","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.phrs.2015.03.004_bib0410","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40272-013-0024-6","article-title":"Safety and pharmacokinetics of atypical antipsychotics in children and adolescents","volume":"15","author":"Caccia","year":"2013","journal-title":"Paediatr. Drugs"},{"issue":"Suppl. 1","key":"10.1016\/j.phrs.2015.03.004_bib0415","doi-asserted-by":"crossref","first-page":"I9","DOI":"10.1007\/s007870070015","article-title":"Atypical neuroleptics in child and adolescent psychiatry","volume":"9","author":"Remschmidt","year":"2000","journal-title":"Eur. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.phrs.2015.03.004_bib0420","first-page":"124","article-title":"First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents","volume":"19","author":"Panagiotopoulos","year":"2010","journal-title":"J. Can. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.phrs.2015.03.004_bib0425","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/j.2051-5545.2009.tb00199.x","article-title":"Metabolic syndrome in people with schizophrenia: a review","volume":"8","author":"De Hert","year":"2009","journal-title":"World Psychiatry"},{"key":"10.1016\/j.phrs.2015.03.004_bib0430","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/JCP.0b013e318297980e","article-title":"Weight gain in risperidone therapy: investigation of peripheral hypothalamic neurohormone levels in psychotic patients","volume":"33","author":"Yanik","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2015.03.004_bib0435","first-page":"177","article-title":"Tolerability and safety profile of risperidone in a sample of children and adolescents","volume":"28","author":"Margari","year":"2013","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2015.03.004_bib0440","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2015.03.004_bib0445","first-page":"e01","article-title":"Addressing adverse effects of antipsychotic treatment in young patients with schizophrenia","volume":"72","author":"Correll","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.phrs.2015.03.004_bib0450","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/10398560801958549","article-title":"Side effects of second-generation antipsychotics: the experiences, views and monitoring practices of Australian child psychiatrists","volume":"16","author":"Walter","year":"2008","journal-title":"Australas"},{"key":"10.1016\/j.phrs.2015.03.004_bib0455","first-page":"13","article-title":"Trends in antipsychotic drug use by very young, privately insured children","volume":"49","author":"Olfson","year":"2010","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.phrs.2015.03.004_bib0460","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/hup.1097","article-title":"Risperidone associated weight, leptin, and anthropometric changes in children and adolescents with psychotic disorders in early treatment","volume":"25","author":"Maayan","year":"2010","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.phrs.2015.03.004_bib0465","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/JCP.0b013e31822befa9","article-title":"The effect of long-term use of risperidone on body weight of children with an autism spectrum disorder","volume":"31","author":"Demb","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2015.03.004_bib0470","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1089\/cap.2009.0071","article-title":"Risperidone-induced weight gain in referred children with autism spectrum disorders is associated with a common polymorphism in the 5-hydroxytryptamine 2C receptor gene","volume":"20","author":"Hoekstra","year":"2010","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.phrs.2015.03.004_bib0475","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1089\/cap.2000.10.259","article-title":"Risperidone-associated weight gain in children and adolescents: a retrospective chart review","volume":"10","author":"Martin","year":"2000","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.phrs.2015.03.004_bib0480","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1089\/cap.2011.0015","article-title":"Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents","volume":"21","author":"Maayan","year":"2011","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.phrs.2015.03.004_bib0485","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1089\/cap.2008.007","article-title":"Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents","volume":"19","author":"Calarge","year":"2009","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"Suppl. 2","key":"10.1016\/j.phrs.2015.03.004_bib0490","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S0924-9338(10)71701-6","article-title":"From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics","volume":"25","author":"Correll","year":"2010","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.phrs.2015.03.004_bib0495","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.coph.2011.02.007","article-title":"The role of serotonin receptors in the action of atypical antipsychotic drugs","volume":"11","author":"Meltzer","year":"2011","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.phrs.2015.03.004_bib0500","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-3-642-25761-2_2","article-title":"Role of dopamine D(2) receptors for antipsychotic activity","author":"Ginovart","year":"2012","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.phrs.2015.03.004_bib0505","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1089\/104454601750143348","article-title":"Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial","volume":"11","author":"van Bellinghen Mand de Troch","year":"2001","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.phrs.2015.03.004_bib0510","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pnpbp.2009.11.009","article-title":"The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain?","volume":"34","author":"Deng","year":"2010","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2015.03.004_bib0515","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.psyneuen.2014.06.010","article-title":"Betahistine ameliorates olanzapine-induced weight gain through modulation of histaminergic, NPY and AMPK pathways","volume":"48","author":"Lian","year":"2014","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.phrs.2015.03.004_bib0520","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.psyneuen.2014.01.018","article-title":"Hypothalamic histamine H1 receptor-AMPK signaling time-dependently mediates olanzapine-induced hyperphagia and weight gain in female rats","volume":"42","author":"He","year":"2014","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.phrs.2015.03.004_bib0525","doi-asserted-by":"crossref","first-page":"e20571","DOI":"10.1371\/journal.pone.0020571","article-title":"Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation","volume":"6","author":"Fern\u00f8","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.phrs.2015.03.004_bib0530","doi-asserted-by":"crossref","first-page":"e33548","DOI":"10.1371\/journal.pone.0033548","article-title":"Alterations to melanocortinergic GABAergic and cannabinoid neurotransmission associated with olanzapine","volume":"7","author":"Weston-Green","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.phrs.2015.03.004_bib0535","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1017\/S1461145713001697","article-title":"Hypothalamic ghrelin signalling mediates olanzapine induced hyperphagia and weight gain in female rats","volume":"17","author":"Zhang","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2015.03.004_bib0540","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.peptides.2005.02.028","article-title":"The neuronal histamine H(1) and pro-opiomelanocortin-melanocortin 4 receptors: independent regulation of food intake and energy expenditure","volume":"27","author":"Yoshimatsu","year":"2006","journal-title":"Peptides"},{"key":"10.1016\/j.phrs.2015.03.004_bib0545","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000090982","article-title":"Histaminergic neurons are involved in the orexigenic effect of orexin-A","volume":"82","author":"Jorgensen","year":"2005","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.phrs.2015.03.004_bib0550","doi-asserted-by":"crossref","first-page":"e104160","DOI":"10.1371\/journal.pone.0104160","article-title":"Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment","volume":"9","author":"Lian","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.phrs.2015.03.004_bib0555","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1163\/156939105774647394","article-title":"mRNA expression levels of leptin-related substances can be modified in risperidone-injected rats","volume":"19","author":"Ota","year":"2005","journal-title":"Biogenic Amines"},{"key":"10.1016\/j.phrs.2015.03.004_bib0560","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.brainres.2014.10.070","article-title":"Effects of risperidone treatment on the expression of hypothalamic neuropeptide in appetite regulation in Wistar rats","volume":"1596","author":"Kursungoz","year":"2015","journal-title":"Brain Res."},{"key":"10.1016\/j.phrs.2015.03.004_bib0565","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1046\/j.1440-1681.2002.t01-1-03755.x","article-title":"Peripheral injection of risperidone, an atypical antipsychotic, alters the bodyweight gain of rats","volume":"29","author":"Ota","year":"2002","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.phrs.2015.03.004_bib0570","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1176\/appi.ajp.159.6.1055","article-title":"Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine","volume":"159","author":"Gothelf","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.phrs.2015.03.004_bib0575","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/ejcn.2013.253","article-title":"The effects of second-generation antipsychotics on food intake, resting energy expenditure and physical activity","volume":"68","author":"Cuerda","year":"2014","journal-title":"Eur. J. Clin. Nutr."},{"key":"10.1016\/j.phrs.2015.03.004_bib0580","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1177\/0269881112449396","article-title":"Reducing olanzapine-induced weight gain side-effect by betahistine: a study in the rat model","volume":"26","author":"Deng","year":"2012","journal-title":"J. Psychopharmacol. (Oxf.)"},{"key":"10.1016\/j.phrs.2015.03.004_bib0585","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.pnpbp.2014.02.003","article-title":"Olanzapine reduced brown adipose tissue thermogenesis and locomotor activity in female rats","volume":"51","author":"Zhang","year":"2014","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2015.03.004_bib0590","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.bbr.2010.10.039","article-title":"Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats","volume":"217","author":"Weston-Green","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.phrs.2015.03.004_bib0595","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ejphar.2007.09.010","article-title":"Antipsychotic-induced suppression of locomotion in juvenile, adolescent and adult rats","volume":"578","author":"Wiley","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2015.03.004_bib0600","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0149-7634(03)00005-8","article-title":"Trajectories of brain development: point of vulnerability or window of opportunity","volume":"27","author":"Andersen","year":"2003","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.phrs.2015.03.004_bib0605","series-title":"The Rat Brain in Sterotaxic Coordinates","author":"Paxinos","year":"2007"},{"key":"10.1016\/j.phrs.2015.03.004_bib0610","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nprot.2008.73","article-title":"Analyzing real-time PCR data by the comparative C(T) method","volume":"3","author":"Schmittgen","year":"2008","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.phrs.2015.03.004_bib0615","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1097\/00004583-200209000-00002","article-title":"Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs","volume":"41","author":"Snyder","year":"2002","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.phrs.2015.03.004_bib0620","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1176\/appi.ajp.163.3.402","article-title":"A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders","volume":"163","author":"Reyes","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.phrs.2015.03.004_bib0625","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1089\/cap.2006.16.575","article-title":"Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy","volume":"16","author":"Luby","year":"2006","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.phrs.2015.03.004_bib0630","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1399-5618.2009.00750.x","article-title":"Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study","volume":"11","author":"Haas","year":"2009","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.phrs.2015.03.004_bib0635","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00213-005-0131-3","article-title":"Effects of sub-chronic antipsychotic drug treatment on body weight and reproductive function in juvenile female rats","volume":"182","author":"Fell","year":"2005","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.phrs.2015.03.004_bib0640","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ajp.2012.05.005","article-title":"Are there different neural mechanisms responsible for three stages of weight gain development in anti-psychotic therapy: temporally based hypothesis","volume":"5","author":"Pai","year":"2012","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.phrs.2015.03.004_bib0645","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/026988110201600402","article-title":"Characterization of olanzapine-induced weight gain in rats","volume":"16","author":"Goudie","year":"2002","journal-title":"J. Psychopharmacol. (Oxf.)"},{"key":"10.1016\/j.phrs.2015.03.004_bib0650","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.pnpbp.2004.08.001","article-title":"Comparative effects of the antipsychotics sulpiride and risperidone in female rats on energy balance, body composition, fat morphology and macronutrient selection","volume":"28","author":"Baptista","year":"2004","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2015.03.004_bib0655","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.physbeh.2008.11.011","article-title":"Risperidone alters food intake, core body temperature, and locomotor activity in mice","volume":"96","author":"Cope","year":"2009","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.phrs.2015.03.004_bib0660","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0006-8993(02)03616-8","article-title":"Comparative effects of the antipsychotics sulpiride or risperidone in rats. I. Bodyweight, food intake, body composition, hormones and glucose tolerance","volume":"957","author":"Baptista","year":"2002","journal-title":"Brain Res."},{"key":"10.1016\/j.phrs.2015.03.004_bib0665","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.neuropharm.2006.07.006","article-title":"Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats","volume":"51","author":"Lin","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2015.03.004_bib0670","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.bbr.2010.10.039","article-title":"Dosage response of metabolic dysfunction to olanzapine treatment in female Sprague Dawley rats","volume":"217","author":"Weston-Green","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.phrs.2015.03.004_bib0675","series-title":"Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers","author":"FDA","year":"2005"},{"key":"10.1016\/j.phrs.2015.03.004_bib0680","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"Reagan-Shaw","year":"2008","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2015.03.004_bib0685","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s00213-001-0933-x","article-title":"Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats","volume":"159","author":"Aravagiri Mand Marder","year":"2002","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.phrs.2015.03.004_bib0690","series-title":"Janssen Pharmaceuticals I. Risperdal Prescribing Information","year":"2015"},{"key":"10.1016\/j.phrs.2015.03.004_bib0695","series-title":"Atypical Antipsychotics: U.S. Food and Drug Administration-approved Indications and Dosages for Use in Pediatric Patients","author":"FDA","year":"2014"},{"key":"10.1016\/j.phrs.2015.03.004_bib0700","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1124\/jpet.102.046987","article-title":"Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy","volume":"305","author":"Kapur","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2015.03.004_bib0705","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.phrs.2013.01.002","article-title":"Acutely administered antipsychotic drugs are highly selective for dopamine D2 over D3 receptors","volume":"70","author":"McCormick","year":"2013","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2015.03.004_bib0710","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.2174\/092986710794182944","article-title":"Neuronal histamine and its receptors: implication of the pharmacological treatment of obesity","volume":"17","author":"Masaki","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.phrs.2015.03.004_bib0715","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.neulet.2007.11.055","article-title":"Histamine depolarizes neurons in the dorsal vagal complex","volume":"432","author":"Poole","year":"2008","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.phrs.2015.03.004_bib0720","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"Kroeze","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2015.03.004_bib0725","doi-asserted-by":"crossref","first-page":"368","DOI":"10.2133\/dmpk.20.368","article-title":"Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus","volume":"20","author":"Matsui-Sakata","year":"2005","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.phrs.2015.03.004_bib0730","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.psyneuen.2008.01.018","article-title":"Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression","volume":"33","author":"Han","year":"2008","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.phrs.2015.03.004_bib0735","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1073\/pnas.0611417104","article-title":"Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase","volume":"104","author":"Kim","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2015.03.004_bib0740","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0924-9338(13)77354-1","article-title":"2761 \u2013 The role of central neuropeptides in weight gain caused by olanzapine","volume":"28","author":"Sezlev","year":"2013","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.phrs.2015.03.004_bib0745","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/1097-4547(20000815)61:4<458::AID-JNR13>3.0.CO;2-I","article-title":"Effects of typical and atypical antipsychotics on neuropeptide Y in rat brain tissue and microdialysates from ventral striatum","volume":"61","author":"Gruber","year":"2000","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.phrs.2015.03.004_bib0750","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.pbb.2010.05.029","article-title":"Olanzapine causes hypothermia, inactivity, a deranged feeding pattern and weight gain in female Wistar rats","volume":"97","author":"Evers","year":"2010","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.phrs.2015.03.004_bib0755","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/sj.npp.1300791","article-title":"Risperidone pretreatment prevents elevated locomotor activity following neonatal hippocampal lesions","volume":"31","author":"Richtand","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2015.03.004_bib0760","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.bbr.2006.04.004","article-title":"Behavioural effects of chronic haloperidol and risperidone treatment in rats","volume":"171","author":"Karl","year":"2006","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.phrs.2015.03.004_bib0765","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2165\/00023210-200519110-00003","article-title":"Advances in drug treatments for children and adolescents with autism and other pervasive developmental disorders","volume":"19","author":"Malone","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.phrs.2015.03.004_bib0770","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1097\/00004583-199908000-00011","article-title":"Risperidone treatment for juvenile bipolar disorder: a retrospective chart review","volume":"38","author":"Frazier","year":"1999","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.phrs.2015.03.004_bib0775","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1345\/aph.1P397","article-title":"Use of risperidone as augmentation treatment for major depressive disorder","volume":"45","author":"Brown","year":"2011","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.phrs.2015.03.004_bib0780","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40272-013-0016-6","article-title":"Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis","volume":"15","author":"Almandil","year":"2013","journal-title":"Paediatr. Drugs"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661815000365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661815000365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T00:49:34Z","timestamp":1566434974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661815000365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":78,"alternative-id":["S1043661815000365"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2015.03.004","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risperidone-induced weight gain and reduced locomotor activity in juvenile female rats: The role of histaminergic and NPY pathways","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2015.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}